open access publication

Article, 2024

Incidence and survival of primary metastatic breast cancer in Denmark: implication of breast cancer screening, classification, and staging practice

ACTA ONCOLOGICA, ISSN 0284-186X, 0284-186X, Volume 63, Pages 277-287, 10.2340/1651-226X.2023.37270

Contributors

Berg, Tobias (Corresponding author) [1] [2] [3] Jensen, Maj-Britt [1] [2] [3] Rossing, Maria [1] [2] Axelsen, Christian Tang [4] Kuemler, Iben [1] [5] Sondergaard, Lise [6] Vogsen, Marianne 0000-0002-6124-4063 [7] [8] Knoop, A. 0000-0003-2898-1093 [1] [2] [3] Ejlertsen, Bent [1] [2] [3]

Affiliations

  1. [1] Copenhagen Univ Hosp, Ctr Genom Med, Rigshosp, Copenhagen, Denmark
  2. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
  3. [2] Copenhagen Univ Hosp, Ctr Genom Med, Rigshosp, Copenhagen, Denmark
  4. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  5. [3] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Danish Breast Canc Grp, Copenhagen, Denmark
  6. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  7. [4] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
  8. [NORA names: AU Aarhus University; University; Denmark; Europe, EU; Nordic; OECD];
  9. [5] Copenhagen Univ Hosp, Herlev Hosp, Dept Oncol, Herlev, Denmark
  10. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];

Abstract

Background: Primary metastatic breast cancer (pMBC) accounts for 5-10% of annual breast cancers with a median survival of 3-4 years, varying among subtypes. In Denmark, the incidence of breast cancer increased until 2010, followed by a stabilisation. Several factors influencing pMBC incidence and survival, including screening prevalence, staging methods, and classification standards, remain pivotal but inadequately documented. Material and method: This retrospective observational study involving pMBC patients diagnosed between 2000 and 2020 encompassed all Danish oncology departments. Data from the Danish Breast Cancer Group database and the National Patient Register included diagnosis specifics, demographics, treatment, and follow-up. Results: Between 2000 and 2020, 3,272 patients were diagnosed with pMBC, a rise from 355 patients in 2000-2004 to 1,323 patients in 2015-2020. The increase was particularly observed in patients aged 70 years or older. Changes in tumour subtypes were observed, notably with a rise in human epidermal growth factor receptor 2 (HER2)-positive cases but a steady distribution of estrogen receptor (ER) status. Diagnostic practices changed over the two decades, with 6% evaluated with PET/CT (positron emission tomography- computed tomography) or CT (computed tomography) with a bone evaluation in 2000-2004 and 65% in 2015-2020. Overall survival (OS) improved from 23 months in 2000-2004 to 33 months in 2015-2020. In patients with ER-positive and HER2-positive disease, the multivariable model showed improved survival by year of diagnosis, and further, patients with ER-negative/HER2-negative disease fared worse the first 2 years after diagnosis. Interpretation: Our study delineates changes in the treatment and survival of pMBC over two decades. Stage migration, screening introduction, and changes in registration practice, however, prevent a valid assessment of a possible causal relationship.

Keywords

Breast cancer, epidemiology, metastatic

Data Provider: Clarivate